NCT03239626 is a NA clinical trial of POHIM-RT in Cervix Cancer, sponsored by Samsung Medical Center.

Who is sponsoring NCT03239626?

NCT03239626 is sponsored by Samsung Medical Center.

What drugs are being tested in NCT03239626?

Interventions in NCT03239626: POHIM-RT.

What condition does NCT03239626 study?

NCT03239626 studies Cervix Cancer, Radiotherapy, Adjuvant, Radiotherapy, Intensity-Modulated, Hypofractionated Dose.

Is NCT03239626 still recruiting?

NCT03239626 is currently active, enrolled. Last updated 3 January 2025.

Last reviewed 2025-01-03 · How we verify

NCT03239626

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Postoperative Hypofractionated Intensity-modulated Radiation Therapy in Cervical Cancer

Active, enrolled NA Last updated 3 January 2025

What this trial tests

NA trial testing POHIM-RT in Cervix Cancer in 120 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

31 August 2017

Primary endpoint
28 April 2025

28 April 2025

Quick facts

Lead sponsor	Samsung Medical Center
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	120
Start date	31 August 2017
Primary completion	28 April 2025
Estimated completion	28 April 2025
Sites	1 location across South Korea

Drugs / interventions tested

POHIM-RT

Conditions studied

Cervix Cancer — all drugs for Cervix Cancer →
Radiotherapy, Adjuvant — all drugs for Radiotherapy, Adjuvant →
Radiotherapy, Intensity-Modulated — all drugs for Radiotherapy, Intensity-Modulated →
Hypofractionated Dose — all drugs for Hypofractionated Dose →

Sponsor

Samsung Medical Center

Who can join

Adults 20 to 70, female only, with Cervix Cancer or Radiotherapy, Adjuvant. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate the acute toxicities, late toxicities, and treatment results when the early cervical cancer patients are treated by hypofractionated intensity-modulated radiotherapy (2.5 Gy X 16 fractions, once a day) after radical hysterectomy.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

A dummy-run evaluation of postoperative hypofractionated intensity-modulated radiation therapy (POHIM-RT) trials for cervical cancer.
Cho WK, Kim H, Park W, Kim SW, et al · · 2021 · cited 7× · PMID 33392616 · DOI 10.1093/jrr/rraa085
Postoperative hypofractionated intensity-modulated radiation therapy in cervical cancer: prospective phase 2 trial (POHIM_RT study).
Cho WK, Park W, Kim SW, Lee KK, et al · · 2025 · cited 2× · PMID 40449127 · DOI 10.1016/j.ygyno.2025.05.020
Is Moderately Hypofractionated Radiotherapy a Safe and Effective Strategy for Cervical Cancer?-A Review of Current Evidence.
Xiao H, Guo F, Wang Z, Pei K, et al · · 2026 · PMID 41590344 · DOI 10.3390/curroncol33010024

Verify or expand the search:

Other recruiting trials for Cervix Cancer

Currently open trials in the same condition.

NCT07276360 — Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda · Phase 2 · recruiting
NCT07292818 — Hyaluronic Acid-based Gel Spacers in Gynecologic Malignancies · Phase 1 · recruiting
NCT07435623 — Late Radiation Toxicities in Cervical and Endometrial Cancer: A Postoperative IMRT/Brachytherapy Study · recruiting
NCT06904365 — Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women · recruiting
NCT06416748 — Minimally Invasive Simple Hysterectomy in Low Risk Cervical Cancer · NA · recruiting

Other Samsung Medical Center trials

Trials by the same sponsor.

NCT07482865 — Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support · NA · not yet recruiting
NCT07467213 — Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute M · Phase 4 · not yet recruiting
NCT07530913 — Effectiveness Analysis of a Rehabilitation Exercise Platform for Living Donor Liver Transplantation Patients · NA · enrolling by invitation
NCT07500701 — Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Pro · Phase 3 · recruiting
NCT07409441 — Korea Acute Myocardial Infarction Registry · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03239626 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Samsung Medical Center
Last refreshed: 3 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03239626.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing